Overview

Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

Status:
Active, not recruiting

Trial end date:
2022-04-15

Target enrollment:

Participant gender:

Summary

Compare carfizomib, dexamethasone, and daratumumab (KdD) to Carfilzomib and dexamethasone (Kd) in terms of progression free survival (PFS) in participants with multiple myeloma who have relapsed after 1 to 3 prior therapies.

Phase:

Phase 3

Details

Lead Sponsor:

Amgen

Treatments:

Antibodies, Monoclonal
BB 1101
Daratumumab
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate